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System xC is a mediator of microglial function
and its deletion slows symptoms in amyotrophic
lateral sclerosis mice
Pinar Mesci,1 Sakina Zaı̈di,1 Christian S. Lobsiger,1 Stéphanie Millecamps,1 Carole Escartin,2
Danielle Seilhean,1 Hideyo Sato,3 Michel Mallat1 and Séverine Boillée1
Amyotrophic lateral sclerosis is the most common adult-onset motor neuron disease and evidence from mice expressing amyo-
trophic lateral sclerosis-causing SOD1 mutations suggest that neurodegeneration is a non-cell autonomous process where microglial
cells influence disease progression. However, microglial-derived neurotoxic factors still remain largely unidentified in amyotrophic
lateral sclerosis. With excitotoxicity being a major mechanism proposed to cause motor neuron death in amyotrophic lateral
sclerosis, our hypothesis was that excessive glutamate release by activated microglia through their system xC (a cystine/glutamate
antiporter with the specific subunit xCT/Slc7a11) could contribute to neurodegeneration. Here we show that xCT expression is
enriched in microglia compared to total mouse spinal cord and absent from motor neurons. Activated microglia induced xCT
expression and during disease, xCT levels were increased in both spinal cord and isolated microglia from mutant SOD1 amyo-
trophic lateral sclerosis mice. Expression of xCT was also detectable in spinal cord post-mortem tissues of patients with amyo-
trophic lateral sclerosis and correlated with increased inflammation. Genetic deletion of xCT in mice demonstrated that activated
microglia released glutamate mainly through system xC. Interestingly, xCT deletion also led to decreased production of specific
microglial pro-inflammatory/neurotoxic factors including nitric oxide, TNFa and IL6, whereas expression of anti-inflammatory/
neuroprotective markers such as Ym1/Chil3 were increased, indicating that xCT regulates microglial functions. In amyotrophic
lateral sclerosis mice, xCT deletion surprisingly led to earlier symptom onset but, importantly, this was followed by a significantly
slowed progressive disease phase, which resulted in more surviving motor neurons. These results are consistent with a deleterious
contribution of microglial-derived glutamate during symptomatic disease. Therefore, we show that system xC participates in
microglial reactivity and modulates amyotrophic lateral sclerosis motor neuron degeneration, revealing system xC inactivation,
as a potential approach to slow amyotrophic lateral sclerosis disease progression after onset of clinical symptoms.
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Introduction
Amyotrophic lateral sclerosis (ALS) is characterized by loss
of upper and lower motor neurons leading to progressive
paralysis and death of patients. Although mainly sporadic,
10% of ALS cases are inherited and the second most
frequent cause of familial ALS are dominant mutations in
the gene encoding Cu/Zn superoxide dismutase (SOD1)
(Rosen et al., 1993). As of today, the animal models
recapitulating closest ALS symptoms are mice and rats
expressing mutant human SOD1 (while expression of wild-
type human SOD1 does not lead to disease) (Boillee et al.,
2006a). In these models, ubiquitous expression of mutant
SOD1 leads to progressive motor neuron death through
an unknown gain-of-toxic function for which several
hypotheses have been proposed including excitotoxicity
and neuroinflammation (Boillee et al., 2006a). In addition,
motor neuron death involves a non-cell autonomous
mechanism, with neighbouring non-neuronal cells part-
icipating in the disease (Clement et al., 2003; Beers et al.,
2006; Boillee et al., 2006b; Yamanaka et al., 2008;
Lobsiger et al., 2009; Kang et al., 2013). In particular,
reducing mutant SOD1 expression selectively in microglial
cells/macrophages, strongly slowed down disease progression
in ALS mice (Beers et al., 2006; Boillee et al., 2006b; Wang
et al., 2009).
Microglial cells are the macrophages of the CNS.
They are known to respond to any CNS insult including
during neurodegenerative diseases and their responses
can have both neuroprotective and neurotoxic effects
(Czeh et al., 2011). By analogy to macrophages, microglial
cells are able to modify their phenotypes from an
anti-inflammatory/neuroprotective (M2) to a pro-inflamma-
tory/neurotoxic (M1) state, with M1/M2 being the
two extremes of a phenotype continuum. These phenotype
changes are thought to occur during chronic neurode-
generative conditions, and have been detected in spinal
cords of ALS mice (Beers et al., 2011; Liao et al., 2012).
The consequences of these changes on the actual ALS
disease course are still largely unknown. A hint comes
from administration of minocycline in ALS mice, which
impacted global M1/M2 microglial polarization
(Kobayashi et al., 2013), however, minocycline is also
known to have direct anti-apoptotic actions on motor
neurons themselves (Zhu et al., 2002). In addition,
genetic deletion of the superoxide-producing enzyme
NOX2/cybb (strongly expressed in microglia), suggested
that reducing a specific M1-phenotype related factor
could benefit disease in ALS mice (Wu et al., 2006;
Marden et al., 2007).
Therefore, as a strong candidate implicated in disease,
targeting microglia to slow down ALS disease progression
could best be achieved by both maintaining microglia in an
anti-inflammatory/neuroprotective (M2) state, and blocking
the disease-relevant pro-inflammatory/neurotoxic (M1)
microglial-derived factors.
As part of preventing neurotoxicity, we focused on
glutamate excitotoxicity, one of the longest standing
proposed pathological mechanisms for ALS. Motor neurons
are highly sensitive to glutamate excitotoxicity, especially
in the context of ALS-linked mutations (Rothstein et al.,
1995; Van Den Bosch et al., 2006), as most recently shown
using neurons derived from human-induced pluripotent stem
cells carrying the C9orf72 mutation (Donnelly et al., 2013).
ALS-associated glutamate excitotoxicity could also be
promoted by non-cell autonomous mechanisms, as motor
neuron neighbouring astrocytes show decreased expression
of reuptake transporters for synaptic glutamate, both in ALS
mice/rats and human tissues (Rothstein et al., 1995;
Howland et al., 2002). Importantly, microglia on their
own could also directly contribute to ALS-associated excito-
toxicity, as they can release glutamate (Qin et al., 2006;
Maezawa and Jin, 2010; Takeuchi et al., 2011). We now
propose that system xC could be a major contributor
of microglial-derived glutamate. System xC is a cystine/
glutamate antiporter capturing extracellular cystine,
used for glutathione synthesis, in exchange for glutamate
release. It is composed of two subunits, one common to
several amino acid transporters, SLC3A2, and a specific
one, xCT/Slc7a11, a 12 transmembrane domain protein
that forms the channel (Sato et al., 1999; Gasol et al.,
2004). System xC, although considered a more glial
than neuronal transporter, is also known to be expressed
by the macrophage lineage (Watanabe and Bannai, 1987;
Piani and Fontana, 1994; Sato et al., 2001) and has
been detected in reactive microglia of Alzheimer’s disease
model mice (Qin et al., 2006) however, its microglial
expression and regulation in ALS mice has so far not been
assessed.
We hypothesized that modulation of system xC in ALS
could be beneficial in two ways. First, activated microglia
could release excessive glutamate. Thus, system xC deletion
would reduce glutamate excitotoxicity. Second, both extra-
cellular glutamate and intracellular glutathione can influ-
ence microglial activation, by acting through microglial
expressed glutamate receptors (Kaindl et al., 2012;
Lewerenz et al., 2013) or by acting (in the case of gluta-
thione) on redox modulated intracellular microglial signal-
ling cascades (Ogunrinu and Sontheimer, 2010; Lewerenz
et al., 2013). Thus, system xC suppression could directly
influence the microglial M1/M2 polarization state during
ALS disease progression.
With the present study, we therefore used xCT (Slc7a11)
gene deletion, to assess if modulation of system xC can
influence overall microglial reactivity and therefore disease
course and motor neuron degeneration in mutant SOD1
ALS mice.
Materials and methods
Additional information is supplied in the online Supplementary
material.
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Animals
Mice were hSOD1G85R, hSOD1G37R (Boillee et al., 2006b),
control hSOD1WT [C57Bl/6-Tg(SOD1)3Cje/J, Jackson
Laboratory], and mice deleted for the Slc7a11 gene (xCT/
mice) (Sato et al., 2005), all on a C57BL/6J background
(Janvier). All procedures were performed in accordance with
the guidelines for care and use of experimental animals of the
European Union and approved by the ethics committee for
animal experimentation n5 in Ile-de-France.
Survival analysis
A two-step mating strategy gave hSOD1G37R:xCT/ (n = 21),
hSOD1G37R:xCT + / (n = 35) and hSOD1G37R:xCT + / + (n = 24)
mice, which were weighted weekly as an objective and un-
biased measure of disease course (Boillee et al., 2006b;
Lobsiger et al., 2009) and their grip strength measured
(Bioseb, grip test). The three groups of mice started with com-
parable weight and grip-strength means.
Primary microglial cell culture
Cells were derived from postnatal Day 0 or 1 mouse pup
cerebral cortex according to Thery et al. (1991). Highly pure
microglia (499%, quantified after immunostaining with
microglial specific antibodies CD11b/Itgam, F4/80/Emr1 and
Hoechst 33342 nuclear staining dye) were plated for the dif-
ferent assays and their survival measured. For immunostaining
anti-xCT (Novus Bio; 1:5000), anti-CD11b (Serotec, 1:400)
and F4/80 (Serotec, 1:100) antibodies were used.
Fluorescence signal (integrated density) was measured per cell
and compared to the control condition (xCT + / + microglia
without lipopolysaccharide treatment), using ImageJ software
(n = 3 experiments per genotype).
Glutamate assay
Glutamate released (for 30 h after adding lipopolysaccharide,
20 000 cells/well, n = 3–4 experiments per genotype and treat-
ment) was measured with the glutamate dehydrogenase-based
colorimetric assay of Beutler (1985).
Nitric oxide assay
Nitric oxide production was assessed by measuring nitrite
levels (a stable by-product of nitric oxide) with the colorimetric
Griess method for 50 000 cells/well (n = 3 experiments per
genotype and treatment).
Luminex assay
Microglia were plated at a density of 5  104 cells/96-
well-plates (5–6 wells/condition, n = 3–4 experiments per geno-
type and treatment). All samples (25 ml of medium) were run in
duplicates with Milliplex Map kits and analysed with the
Magpix system (Life Technologies).
Glutathione assay
Total glutathione levels were measured in the spinal cord of 1-
year-old mice using the QuantiChrom Glutathione Assay Kit
(BioAssay Systems).
RNA extraction and real-time PCR
RNA extraction for tissues and cells was performed with
Qiagen RNeasy Kits (Qiagen). Reverse transcription was per-
formed with SuperScript III (Life Technologies) using 500 ng
of RNA for spinal cord tissues, 250 ng for cultures and human
spinal cord tissues, and 20 ng or 2 ng for laser-microdissected
motor neurons and adult mouse spinal cord microglia, respect-
ively. Quantitative PCRs were performed with SYBR Green
Master Mix (Applied Biosystems).
Laser microdissection of motor
neurons
Motor neuron laser microdissection was performed as previ-
ously described (Lobsiger et al., 2007). From one lumbar (L4–
L6) spinal cord, 350 motor neurons were collected yielding
20 ng of RNA.
Isolation of microglia from adult
mouse spinal cord
Microglial cells were isolated as described by De Groot et al.
(2000), followed by purification with anti-CD11b microbead-
coupled antibodies and Miltenyi MS columns. Approximately
7–10  104 CD11b + cells were recovered from one control
spinal cord.
Immunohistochemistry on spinal
cord tissues
Thirty-micrometre paraformaldehyde fixed cryosections were
stained with: anti-Iba1 (Wako Chemicals, 1:500), anti-Mac-2
(Cederlane, 1:500), anti-GFAP (Dako, 1:4000) and anti-ChAT
(Millipore, 1:200) for n = 3–4 animals per genotype and per
time point.
Motor neuron counts
Motor neuron numbers were determined from 30-mm serial
sections across the entire lumbar spinal cord and counted in
every 12th ChAT stained section corresponding to a total of
23–26 sections per animal for n = 3 animals per genotype and
time point.
Human samples
Patients with ALS were enrolled in a brain donation pro-
gramme declared to the Ministry of Research and
Universities, as requested by French Law. An explicit con-
sent was signed by the patient, or by the next of kin, in the
name of the patient, in accordance with the French Bioethical
Laws.
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Immunoblots
Proteins (16 mg) were separated on NuPAGETM 4–12% Bis–
Tris Gel (Invitrogen) and electrophoretically transferred to
nitrocellulose membranes stained with anti-xCT (Abcam;
1:1500) and anti-beta-actin (Sigma; 1:6000) antibodies.
Statistical analysis
Two-way ANOVA tests followed by a Bonferroni multiple
comparison test were used to compare groups with different
genotypes and different treatments (with or without lipopoly-
saccharide). One-way ANOVA tests followed by a Bonferroni
multiple comparison test were used to compare multiple
groups, Student’s t-test to compare means of two groups and
Kaplan-Meier Log Rank test for survival curves.
Results
Primary microglial cells express
system xC and xCT levels are
increased on microglial activation
To study the implication of system xC and microglial glu-
tamate release in ALS, we first studied the expression of
system xC in primary mouse microglial cells. The mRNA
for xCT, the specific subunit of system xC, was expressed
by control (xCT + / + ) microglia and strongly increased (18-
fold) when cells were activated with lipopolysaccharide, the
most commonly used factor to activate microglia (Fig. 1A).
At a protein level, xCT was present in the cytoplasm and
on the plasma membrane of xCT + / + microglia (with the
signal absent in xCT/ cells) (Fig. 1B) and likewise
strongly increased (3-fold) upon activation with lipopoly-
saccharide (Fig. 1B and C). Next, we confirmed that pri-
mary microglial cells from both mutant (hSOD1G37R,
hSOD1G85R) and wild-type (hSOD1WT) human SOD1 ex-
pressing mice were also able to induce xCT levels after
lipopolysaccharide activation (Fig. 1A and C).
Figure 1 xCT, the specific subunit of system xC is expressed
by primary mouse microglial cells and its level increases
upon microglial activation. xCT levels were measured in primary
microglial cells from mice expressing xCT (xCT+ / + ), or not
(xCT/), heterozygous for xCT (xCT + /) or expressing different
Figure 1 Continued
forms of mutant (hSOD1G37R, hSOD1G85R) or wild-type (hSOD1WT)
hSOD1, after lipopolysaccharide (LPS, 100 ng/ml) treatment or in
(non-treated) control conditions. (A) Microglial xCT mRNA levels
measured by reverse-transcription quantitative PCR and normalized
to the housekeeping gamma-actin (Actg1) gene. Results are shown
relative to non-treated control microglia (xCT+ / + ). (B)
Representative pictures of cultured microglial cells stained with anti-
xCT antibodies (green) and fluorescent nuclear Hoechst stain (blue).
(C) xCT immunofluorescent intensities (integrated densities per cell)
measured for each cell. Bars represent means of fold changes,  SEM;
*P5 0.05, **P5 0.01 and ***P5 0.001, two-way ANOVA with
Bonferroni multiple comparison test, relative to non-treated cells of
the same genotype; n = 3 experiments per genotype; n.s. = non-
significant. Scale bar in B = 50mm.
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Importantly, as no differences between wild-type hSOD1,
mutant hSOD1 or non-transgenic microglia were detected,
these results suggest that induction of system xC was solely
dependent on the microglial activation state and not the
presence of a specific ALS-linked gene mutation.
Deletion of xCT reduces the
pro-inflammatory phenotype of
activated primary microglia
To study system xC involvement in glutamate release by pri-
mary microglial cells (and linked to it, its potential contribu-
tion in excitotoxicity), we measured glutamate concentration
in culture medium. Unstimulated microglia released glutam-
ate at 10–50 mM after 30 h in culture and this increased by
70% upon lipopolysaccharide activation (Fig. 2A).
Importantly, xCT deletion in microglial cells from xCT/
mice, led to a 70% decrease in glutamate release compared
to control (xCT + / + ) microglia (Fig. 2A). In addition, treating
xCT/ microglial cells with lipopolysaccharide did not raise
glutamate production (Fig. 2A). Therefore, our findings show
that microglial cells release glutamate mainly through their
system xC. Of note, mutant or wild-type hSOD1 expressing
microglia released similar amounts of glutamate as control
microglia, both with and without lipopolysaccharide activa-
tion (Fig. 2B). These data show (similar to the xCT expres-
sion, above) that glutamate release did not depend on the
presence of mutant or wild-type hSOD1 but solely on the
microglial activation state.
Although system xC blockers are known to lack specifi-
city (Lewerenz et al., 2013), we tested one, sulfasalazine,
and found that it blocked microglial glutamate release both
in control conditions and after lipopolysaccharide treat-
ment (Fig. 2C), consistent with system xC being responsible
for the measured glutamate release.
To test our hypothesis that xCT deletion would not just
reduce excessive glutamate release, but could also directly
influence the global M1/M2 activation state, we assessed
microglial production of known pro-inflammatory/neuro-
toxic (M1) and anti-inflammatory/neurotrophic (M2) fac-
tors. First, the classic microglial neurotoxic (M1) factor
nitric oxide was assessed. Lipopolysaccharide strongly
induced (by 10-fold) microglial nitric oxide production,
whereas xCT deletion led to 65% less nitric oxide produc-
tion upon lipopolysaccharide activation (Fig. 3A). Next,
using a multiplex enzyme-linked immunosorbent assay
(Luminex), different growth factors (G-CSF/Csf3, GM-
CSF/Csf2, VEGFa), cytokines (TNFa, IFNg, IL1a, IL1b,
IL3, IL4, IL6, IL10, IL12b, IL13, IL17) and chemokines
(CCL5, CCL2, CCL3, CCL4) were measured in media con-
ditioned by control (xCT + / + ) or xCT/ microglia, acti-
vated or not by lipopolysaccharide (Fig. 3B–E and
Supplementary Fig. 1). Except for IL13 and IFNg, which
were not detectable, all the factors assessed were released
by microglia. Interestingly, compared to controls, in
xCT-deleted microglia, we found a significant
downregulation of the lipopolysaccharide-induced produc-
tion of the growth factor G-CSF/Csf3 (80%, Fig. 3D), but
also of the pro-inflammatory factors TNFa (60%, Fig.
3B), IL6 (70%, Fig. 3C), and the chemokine CCL3
(25%, Fig. 3E). Of note, not all measured factors were
Figure 2 System xC deletion or inhibition strongly reduces
glutamate release from primary mouse microglial cells.
Glutamate release was measured in the culture medium of primary
microglial cells from mice expressing (xCT + / + ) or not (xCT/)
xCT, heterozygous for xCT (xCT+ /) or expressing different forms
of mutant (hSOD1G37R, hSOD1G85R) or wild-type (hSOD1WT)
hSOD1, after lipopolysaccharide (LPS, 100 ng/ml) treatment or in
(non-treated) control (CON) conditions. (A and B) Glutamate levels
are shown relative to non-treated control microglia (xCT + / + ) (A),
or non-transgenic littermate control C57BL/6J microglia (B6) (B).
Note that because of variability, the apparent trend of increased
glutamate release in lipopolysaccharide-treated hSOD1WT microglia
was not statistically significant. (C) Glutamate levels in media of
control microglia (B6), treated or not with lipopolysaccharide and
increasing concentrations of sulfasalazine (SSZ). Bars represent
means of percentages,  SEM; *P5 0.05 and ***P5 0.001, two-way
ANOVA with Bonferroni multiple comparison test; n = 3 experi-
ments per genotype in A, and B and per dose of sulfasalazine in C.
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dependent on xCT expression; CCL2 production was
stable, underlining the specificity of the changes found
(Supplementary Fig. 1).
Thus, as upon activation, xCT-deleted microglial cells
released not just less glutamate, but also less nitric oxide
and other pro-inflammatory/neurotoxic (M1) factors,
system xC can therefore be considered a regulator of the
microglial activation state.
xCTexpression is increased in microglia
of ALS mice and correlates with
inflammation in human ALS spinal cord
Although system xC is considered a rather glial transporter,
its lack of expression by adult motor neurons was not known,
but was an essential requirement for our non-cell
autonomous hypothesis. Thus, we established, by comparing
xCT mRNA expression from isolated, laser-microdissected,
adult motor neurons to whole lumbar spinal cord, that motor
neurons did not express significant levels of system xC in con-
trol and mutant SOD1 ALS mice (Fig. 4A and Supplementary
Fig. 2B), indicating that potential changes of xCT expression
and effects of xCT deletion during disease, cannot be linked to
a contribution of motor neurons.
Because primary microglial cells, when activated,
increased xCT expression and as microglia are activated
during ALS, we analysed lumbar spinal cord xCT mRNA
expression at four different disease stages in slowly pro-
gressing mutant hSOD1G37R ALS mice, which reach end
stage on average at 13.5 months (Fig. 4B). In non-transgenic
control mice, xCT levels were not modified during ageing,
and wild-type hSOD1WT did not influence xCT expression
(Supplementary Fig. 2A). Importantly, however, in ALS
Figure 3 xCT deletion reduces production of the pro-inflammatory/neurotoxic factors nitric oxide, TNFa and IL6 by lipo-
polysaccharide activated primary mouse microglial cells. Different factors were measured in the culture medium of primary microglial
cells from mice expressing xCT (xCT + / + ) or not (xCT/), after lipopolysaccharide (LPS, 100 ng/ml) treatment or in (non-treated) control
conditions. (A) Levels of nitric oxide (NO) production (measured in the culture medium through its stable by-product, nitrite) by microglial cells
are shown relative to non-treated control microglia (xCT+ / + ). Note that xCT/ microglial cells produce less nitric oxide than xCT + / +
microglial cells when activated by lipopolysaccharide. (B–E) Results from microglial cytokines: TNFa (B), IL6 (C); growth factors: G-CSF/Csf3
(D) and chemokines: MIP-1/CCL3 (E). Results represent amounts of factors released in the culture medium as measured by a multiplex Luminex
assay. Here are shown the factors which were different between xCT/ and xCT+ / + microglial cells. For additional protein factors measured,
see Supplementary Fig. 1. Bars represent means of amounts  SEM; all lipopolysaccharide treated xCT + / + groups are significantly different
(P5 0.01) compared with non-treated; *P5 0.05, **P5 0.01, two-way ANOVA with Bonferroni multiple comparison test, n = 3–4 experiments
for each genotype.
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mice, xCT expression, while unchanged presymptomatically,
was strongly increased at both disease onset and symptomatic
stages, and then decreased at end stage (Fig. 4B).
To analyse whether microglial cells were a major source of
disease-associated increased xCT expression, we isolated
adult microglia from spinal cords of ALS mice during dis-
ease. First, compared to whole lumbar spinal cord, xCT
mRNA was clearly enriched in microglia (Fig. 4A).
Isolated microglia expressed mRNA for the microglial/
macrophage marker CD68 and to higher levels when iso-
lated from symptomatic compared to presymptomatic ALS
mouse spinal cords (Supplementary Fig. 2C). Consistent with
a contribution from activated microglia to disease-associated
xCT induction, xCT mRNA levels were strongly increased in
isolated microglia during disease progression (by 45-fold be-
tween symptomatic and presymptomatic stages) (Fig. 4C).
Importantly, xCT mRNA and protein were also ex-
pressed in the spinal cord of human ALS cases and xCT
mRNA levels correlated with levels of CD68 (Fig. 4D and
Supplementary Table 1) in agreement with our results in
mice where xCT expression was increased when microglial
cells were activated.
Deletion of xCT in ALS mice leads to
increased expression of M2 markers,
suggesting a switch towards a more
neuroprotective microglial phenotype
As deleting xCT reduced neurotoxic factor production of
cultured microglia, and microglial xCT expression was
increased during disease in ALS mice, we next investigated
the impact of xCT deletion on microglial phenotype,
in vivo, over the course of the disease. Therefore, we
crossed hSOD1G37R mice with xCT/ mice.
First, we analysed general microgliosis in lumbar spinal
cords of ALS mice, deleted or not for xCT, over the course
of the disease, by using the classic microglial markers Iba1/
Aif1 and Mac-2/Lgals3 (Fig. 5 and Supplementary Fig. 3).
Although microglial activation increased during the course
of the disease, overall microgliosis (as assessed by Iba1/Aif1
and Mac-2/Lgals3 immunostainings) was comparable be-
tween hSOD1G37R ALS mice with or without xCT, at
every tested disease stage (Fig. 5 and Supplementary Fig. 3).
Figure 4 During disease, xCT mRNA expression is
increased in spinal cord microglia of mutant SOD1 ALS
mice and its expression level correlates with increased in-
flammation in post-mortem human ALS spinal cord tis-
sues. (A–C) xCT mRNA expression was analysed by reverse-
transcription quantitative PCR normalized to gamma-actin (Actg1).
(A) xCT mRNA expression results are shown from fresh frozen
adult non-transgenic control mouse whole lumbar spinal cord tissue
[SC (whole)], laser-microdissected motor neurons from adult non-
transgenic control (LMD MN) or hSOD1G37R [LMD MN (G37R)]
mouse spinal cords, remains of the spinal cord sections devoid of
laser microdissected motor neurons [SC (w/o MN)] and microglial
cells isolated from spinal cords of adult non-transgenic control mice
(adult microglia). Note that xCT mRNA was not detected in motor
neurons and was enriched in microglial cells compared to the spinal
cord. (B) xCT mRNA expression results are shown from non-
transgenic control C57BL/6J (B6) or hSOD1G37R mouse lumbar
spinal cord tissues during disease progression. (C) xCT mRNA
expression results are shown from lumbar spinal cord tissues of
presymptomatic hSOD1G37R mice or adult microglial cells isolated
from hSOD1G37R mouse spinal cords at different disease stages.
Bars represent means of fold-changes,  SEM; results are shown
relative to non-transgenic control whole lumbar spinal cord in A,
non-transgenic hSOD1G37R littermates at 2–4 months of age in B,
and to presymptomatic whole spinal cords (2–4 months of age) in
C; *P5 0.05, ***P5 0.001, one-way ANOVA with Bonferroni
multiple comparison test; n = 3 mice per genotype and time point.
presympt = presymptomatic (2–4 months old); onset = age when
reaching weight peak, considered as the beginning of the disease
(in average, at 8.5 months of age); sympt = the beginning of the
symptomatic phase, defined by 10% of weight loss and when first
motor symptoms become apparent (in average, at 12 months of
age); late sympt = late symptomatic stage, defined by 15% of weight
loss (in average, at 13 months of age) and end stage of disease with
complete hindlimb paralysis (in average, at 13.5 months of age). (D)
Expression of xCT protein (top) and mRNA (bottom) in human ALS
Figure 4 Continued
post-mortem spinal cord tissues. xCT protein (37 kDa) expression
was measured by immunoblotting from spinal cord extracts of five
human ALS cases (1–5) and beta-actin (42 kDa) used as a normalizer
(top). For clinical data see Supplementary Table 1. Levels of xCT
mRNA were measured by quantitative PCR and correlated to levels
of the microglial inflammation marker CD68. Samples were nor-
malized with the housekeeping gene GAPDH (bottom). Linear re-
gression P = 0.0086, b= 1.472, R2 = 0.9270. Note that the samples
that contain the highest levels of mRNA for xCT are also the ones
that have the highest content of CD68 in agreement with increased
expression of xCT under inflammatory conditions.
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As classic microglial activation markers (Iba1/Aif1,
Mac-2/Lgals3) do not necessarily predict more specific
M1/M2 microglial activation states, we compared mRNA
expression levels of specific microglial-associated M1
(iNOS/Nos2, NOX2/Cybb, Il1b, IL12p40/Il12b) and M2
(Ym1/Chil3, Arg1, Igf1) markers, during disease progres-
sion in the lumbar spinal cord of hSOD1G37R:xCT + / + and
hSOD1G37R:xCT/ ALS mice (Fig. 6 and Supplementary
Fig. 4).
In presymptomatic hSOD1G37R ALS mice, the expression
of both M1 and M2 markers was comparable to control
(xCT + / + ) mice (Supplementary Fig. 4A). For the M1 mar-
kers, Il1b and NOX2/Cybb were increased over the course
of the disease (Fig. 6B and C). For the M2 markers, Igf1
was increased over the course of the disease (Fig. 6F),
whereas the patterns of expression of Arg1 and Ym1/
Chil3 were more complex. Indeed, Arg1 expression was
stable during the disease and only increased at end stage
Figure 5 xCT deletion does not affect general microgliosis revealed by Iba1/Aif1 immunoreactivity in mutant SOD1
ALS mice. Representative pictures of immunostainings against the classic microglial marker Iba1/Aif1 in the lumbar spinal cord of
hSOD1G37R:xCT + / + , hSOD1G37R:xCT + / and hSOD1G37R:xCT/ ALS mice, shown at five different stages during the disease course (for def-
initions of disease stages, see Fig. 4 legend). For an additional commonly used microglial marker of general microgliosis (Mac-2/Lgals3), see
Supplementary Fig. 3. Scale bar in O = 100 mm.
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Figure 6 xCT deletion changes the profile of microglial associated M1/M2 markers in spinal cords of mutant SOD1 ALS
mice during disease progression. (A) mRNA expression levels [analysed by reverse-transcription quantitative PCR, normalized to gamma-
actin, (Actg1)] of the M1 markers iNOS/Nos2, NOX2/Cybb, Il1b, IL12p40/Il12b and the M2 markers Ym1/Chil3, Arg1 and Igf1, were measured in
whole lumbar spinal cords of xCT/ and xCT+ / + mice. The same M1/M2 markers were also measured in whole lumbar spinal cords of control
(xCT + / + ) as well as hSOD1G37R:xCT + / + and hSOD1G37R:xCT/ ALS mice over the disease course (B–F); for the M1 markers Il1b (B), Nox2
(C) and the M2 markers Ym1/Chil3 (D), Arg1 (E) and Igf1 (F). Bars represent means  SEM; *P5 0.05, **P5 0.01, *** P5 0.001, Student’s t-test,
compared to control (xCT + / + ) mice; n = 3 mice per genotype and time point. For additional markers, see Supplementary Fig. 4. For definitions of
disease stages, see Fig. 4 legend.
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(Fig. 6E). Ym1/Chil3 levels were increased at the symptom-
atic stage, but transiently decreased to almost control levels
at the late symptomatic stage, to strongly increase again at
disease end stage (Fig. 6D).
Upon deletion of xCT, surprisingly, already at baseline in
non-ALS mice as well as in presymptomatic ALS mice, we
detected a striking difference between xCT/ and xCT + / +
mice for the M2 marker Ym1/Chil3, with mRNA levels
more than 10-fold higher in xCT/ mice (Fig. 6A and
D). This difference (increase in Ym1/Chil3 expression)
was even more striking when directly comparing adult
spinal cord microglial cells isolated from xCT + / + and
xCT/ mice (Supplementary Fig. 5).
Over the disease course, comparing ALS mice with and
without xCT, we could distinguish two different disease
phases, with an early disease phase (onset and symptomatic
stage), where xCT deletion led to an increased expression
of Il1b (M1) and a suppression of Ym1/Chil3 (M2) (Fig.
6B and D) and a late disease phase (late symptomatic
stage), where xCT deletion led to an increased expression
of the neuroprotective M2 markers Ym1/Chil3 and Arg1
(Fig. 6D and E).
Consistent with what we already detected in vitro,
deletion of system xC in ALS mice, conferred a more
anti-inflammatory/neuroprotective microglial-associated
phenotype and this was especially evident in the late disease
phase. This suggested a switch towards a more neuropro-
tective microglial phenotype.
A dual action from xCT deletion
leads to an initial speed-up followed
by a beneficial prolongation of the
symptomatic disease phase
As xCT deletion led to a more anti-inflammatory/neuropro-
tective environment in ALS mouse spinal cords, we fol-
lowed hSOD1G37R mice, deleted or not for xCT to
analyse the consequence of removing xCT on the ALS dis-
ease course.
First, baseline xCT-deleted mice showed no phenotype
and had a normal lifespan (958  27.7 days, n = 20 and
978  25.3 days, n = 24; for xCT + / + and xCT/ mice,
respectively; equally gender-matched). Nevertheless, to
ensure absence of subtle pathological abnormalities related
to ALS, we confirmed lack of motor neuron loss and gen-
eral glial activation in 1-year-old xCT/ mice
(Supplementary Fig. 6A and C). Likewise, although
system xC can contribute to glutathione synthesis, previous
studies already showed that global brain glutathione con-
tent (measured in the striatum and hippocampus) was not
reduced in xCT-deleted mice (De Bundel et al., 2011;
Massie et al., 2011), which we now also confirmed for
spinal cord (Supplementary Fig. 6B).
Next, analysis of disease course showed that xCT
deletion in mutant SOD1 ALS mice had no impact on
disease onset, defined by two methods (Fig. 7A and A’),
(i) the age when reaching weight peak (hSOD1G37R:xCT+/+ :
247  6.5 days, n = 28; hSOD1G37R:xCT+ /: 254 8.8
days, n = 40; hSOD1G37R:xCT/: 242.8  7.8 days,
n = 24); and (ii) the age when reaching grip strength peak
(hSOD1G37R:xCT+/+: 197.6  1.9 days, n = 28; hSOD1G37R:
xCT + /: 191.3  1.2 days, n = 40; hSOD1G37R:xCT/:
183.9  1.9 days, n = 24), consistent with the idea that ef-
fects linked to modulation of microglia should rather con-
tribute to the symptomatic phase of the disease.
Surprisingly, hSOD1G37R :xCT/ mice reached the specific
early disease stage (the beginning of the symptomatic
phase, defined by appearance of motoric symptoms and
10% weight loss) 1 month earlier than hSOD1G37R
:xCT + / + mice (32.5 days; P = 0.0233) (328.4  9.2
days, n = 24 and 360.5  7.7 days, n = 26, respectively)
(Fig. 7B), with a similar speed-up, when defining early dis-
ease by 35% grip strength loss (30.8 days; P = 0.0329)
(Fig. 7B’).
However, this earlier reaching of the symptomatic stage
(10% weight loss) did not decrease survival, with
hSOD1G37R:xCT/ mice reaching end stage (complete
hind limb paralysis) at the same time as hSOD1G37R:
xCT + / + mice (Fig. 7C) (410  6 days, n = 21 and
405  7.5 days, n = 24, respectively). This dual action of
xCT deletion led to: (i) a speed-up to reach early disease
(Fig. 7B, B’ and D) but in contrast, and importantly; (ii) an
increase of the duration of the late disease phase after ap-
pearance of symptoms (the time between 10% weight loss
and end-stage or 35% grip strength loss and end-stage;
+ 28 days, P = 0.0278) in hSOD1G37R:xCT/ mice
(85.5  8.2 days, n = 21) as compared to hSOD1G37R:
xCT + / + mice (57.4  5.9 days, n = 24) (Fig. 7D and
Supplementary Fig. 7).
Our tracking of the mouse cohort consistently indicated
that, after appearance of symptoms, hSOD1G37R :xCT/
mice seemed to live longer and behave better than
hSOD1G37R :xCT + / + mice during the symptomatic phase.
To quantify, we measured the survival time to reach a
defined advanced symptomatic disease stage (20% of
weight loss). The time elapsed, after appearance of symp-
toms, to reach this advanced symptomatic stage was indeed
increased (Supplementary Fig. 7A). Interestingly, and con-
sistent with our observation, while 40% of hSOD1G37R
:xCT + / + mice had already died at this disease stage, this
was the case for only 20% of the hSOD1G37R :xCT/
mice (Fig. 7E). Even more so, compared to hSOD1G37R
:xCT + / + mice, hSOD1G37R :xCT/ mice lived longer
after reaching this disease stage (Fig. 7E and
Supplementary Fig. 7B, P = 0.01, which is underestimated
as n = 17/21 for the hSOD1G37R:xCT/ group and
only n = 15/24 for the hSOD1G37R :xCT + / + group).
In line with this finding, during the late symptomatic
disease phase, hSOD1G37R:xCT/ mice had 20%
(P5 0.05) more remaining grip strength than
hSOD1G37R:xCT + / + mice (57  1.6% and 39  1.7%, re-
spectively) (Fig. 7F).
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Figure 7 xCT deletion in mutant SOD1 ALS mice initially speeds up early disease but then promotes longer survival after
reaching the symptomatic disease stage. (A–C) Kaplan-Meier plots of ages when onset [at weight peak (A) or at grip strength peak (A’)],
early disease [at 10% of weight loss (B) or at 35% of grip strength loss (B’)] and end stage (at complete hindlimb paralysis) (C) were reached in
hSOD1G37R:xCT + / + (blue), hSOD1G37R:xCT + / (green) and hSOD1G37R:xCT/ (orange) mice. Animal numbers (equally gender-mixed) are
indicated in brackets. (B and B’) statistical significant differences (P5 0.05, log-rank) when reaching early disease stage, are indicated between the
hSOD1G37R:xCT/ and the hSOD1G37R:xCT + / + groups. (D, left), early disease duration corresponding to means of differences between ages
when individual animals reached onset and 10% of weight loss. (D, right), late disease duration corresponding to means of differences between
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Deletion of xCT in ALS mice results
in more surviving motor neurons at
disease end stage
The three groups of ALS mice, hSOD1G37R:xCT+ / + ,
hSOD1G37R:xCT+ / and hSOD1G37R:xCT/, started out
with the same number of motor neurons (30.9  0.4,
35.5  4.6 and 33.7  1.0 per spinal cord section, respect-
ively) (Fig. 8) and, as expected, during disease, motor neu-
rons degenerated in hSOD1G37R:xCT+ / + mice with only
35% remaining at end stage (Fig. 8). Interestingly, however,
hSOD1G37R:xCT/ mice had, with 45% remaining, a sig-
nificant increase in survival of motor neurons (Fig. 8). This
suggested an overall less neurotoxic environment and slow-
ing of motor neuron degeneration due to xCT deletion, con-
sistent with our results, in vitro, showing decreased secretion
of pro-inflammatory/neurotoxic (M1) factors from primary
microglial cells (Fig. 3) and, in vivo, with the switch to a
spinal cord environment associated with a more anti-inflam-
matory/neuroprotective (M2) microglial phenotype in late
symptomatic xCT-deleted ALS mice (Fig. 6).
Discussion
In the present study, we found xCT to be expressed in the
spinal cord, consistent with its presence in CNS tissues
(Sato et al., 2002; Burdo et al., 2006; Massie et al.,
2008), but not in motor neurons, in accordance with
system xC considered a glial transporter (Pow, 2001). The
main hurdle to fully characterize cell-specific expression is a
lack of good xCT antibodies, which so far only work in
culture, while for tissues, we also detected signals in xCT-
deleted mice. In culture, both astrocytes and microglia ex-
press xCT (Gochenauer and Robinson, 2001; Allen et al.,
2002; Qin et al., 2006; Markowitz et al., 2007; Lewerenz
et al., 2009). Our findings of xCT enrichment in isolated
microglia compared to whole spinal cord, now show xCT
expression by microglia and give support to a previous
report suggesting (using in situ hybridization) xCT expres-
sion in mouse hippocampal microglia (Qin et al., 2006).
We showed that xCT mRNA levels were increased in
ALS mouse spinal cords, lipopolysaccharide-activated pri-
mary microglia and in isolated microglia from ALS mouse
spinal cords during the disease, suggesting that both micro-
glial activation and proliferation participated in the xCT
increase in the spinal cord (without excluding other glial
cells, such as astrocytes, to contribute).
Only one other study has focused on system xC in ALS
mice, and found a transient increase in system xC activity
in acute spinal cord slices from fast progressing
hSOD1G93A mice (Albano et al., 2013). We did not
detect differences compared to control xCT expression
levels in slow progressing hSOD1G37R mice, and our results
Figure 8 xCT deletion in mutant SOD1 ALS mice leads to an increased number of surviving motor neurons at disease end
stage. (A) Representative pictures of lumbar spinal cords of hSOD1G37R:xCT + / + (left column), hSOD1G37R:xCT + / (middle column) and
hSOD1G37R:xCT/ (right column) mice at presymptomatic (top) and at end stage (bottom), stained with the ChAT antibody to reveal motor
neurons. (B) Motor neuron numbers counted in the lumbar spinal cords at different time points. For definitions of disease stages, see Fig. 4
legend. Bars represent means,  SEM; * P5 0.05, Student’s t-test, n = 3 mice per genotype and time point. Scale bar in A = 100 mm.
Figure 7 Continued
ages when individual animals reached 10% of weight loss and end stage. (E) Survival duration (in days) after reaching a defined advanced
symptomatic disease stage [20% of weight loss (WL)]. Bars represent the proportion of mice (relative to the total number of mice per genotype)
still alive within the indicated time frames. Note that hSOD1G37R:xCT/ mice survive longer after reaching symptoms than hSOD1G37R:xCT + / +
mice. (F) Percentage of the remaining grip strength score at the late symptomatic stage (15% of weight loss) compared to the maximum grip
strength score (at onset). Bars represent means,  SEM, *P5 0.05, **P5 0.01, Student’s t-test; with n = 24 animals for hSOD1G37R:xCT + / + and
n = 21 for hSOD1G37R:xCT/ mice. Additional analyses of disease progression are provided in Supplementary Fig. 7.
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rather suggested that xCT expression was dependent on
microglial activation than presence of mutant SOD1. As
microglial activation is a pathological sign of both familial
and sporadic ALS (Henkel et al., 2004; Turner et al., 2004;
Corcia et al., 2012) and as we found xCT to be expressed
in spinal cords of sporadic ALS cases and to parallel CD68
levels, increased xCT expression and potential deleterious
effects following from it, could be part of a more general
disease mechanism not restricted to defined ALS gene
mutations.
Deletion of xCT in mutant SOD1 ALS mice surprisingly
accelerated onset of symptoms for which we propose two
hypotheses: (i) as system xC is involved in glutathione syn-
thesis (Sato et al., 1999), early reduced antioxidant gluta-
thione levels could be responsible. However, total spinal
cord glutathione content was unchanged in xCT/ mice,
consistent with previous studies in striatum and hippocam-
pus (De Bundel et al., 2011; Massie et al., 2011).
Nevertheless, subtle, cell-specific effects could occur, par-
ticularly via astrocytes, which provide neurons with gluta-
thione (Sagara et al., 1993; Dringen and Hirrlinger, 2003);
and (ii) a transient decrease in neuroprotective/anti-inflam-
matory factors could be implicated. Indeed, we detected
decreased production of G-CSF/Csf3 by activated xCT-
deleted primary microglia, which in the CNS, is considered
neuroprotective (Schneider et al., 2005; Pitzer et al., 2008).
Likewise, in xCT-deleted ALS mice, we detected transient
increased expression of pro-inflammatory IL1b (at onset)
and transient decreased expression of anti-inflammatory
Ym1/Chil3 markers (at the early symptomatic stage).
In numerous previous studies, in which a specific disease-
modifying treatment of mutant SOD1 ALS mice resulted in
an accelerated onset of symptoms, a similar reduced sur-
vival was usually found and mice died earlier (Lambrechts
et al., 2003; Van Damme et al., 2005; Zhang et al., 2011;
Lerman et al., 2012). These examples are consistent with
treatments affecting mainly onset of symptoms. Once symp-
toms appeared, the disease progressed at the same rate and
the final length of the symptomatic disease phase (from
onset of symptoms until end stage) was unchanged.
In our case, xCT deletion accelerated onset of symptoms.
However, and in contrast to the mentioned examples, xCT
deletion in ALS mice did not lead to a reduced survival and
mice did not die earlier, suggesting that xCT deletion, once
symptoms appeared, slowed the rate of disease progression.
Indeed, we found that in xCT-deleted ALS mice (i) time
elapsed after onset of symptoms to reach a defined late
symptomatic stage was increased; (ii) levels of spinal cord
M2 markers were increased; (iii) grip strength during the
late symptomatic phase was better (although, actual motor
neuron numbers were still similar, suggesting that the re-
maining ones were less affected); and finally (iv) more sur-
viving motor neurons remained at end stage. While it is
possible that the dual actions of xCT deletion cannot be
separated, our results strongly suggest a neuroprotective
consequence if system xC activity would be reduced
during the progressive disease phase that follows onset of
symptoms.
Our hypothesis for the slowed disease progression is a
beneficial consequence of xCT-deletion to lower glutamate
secretion. Thus, xCT deletion would help reduce ALS-asso-
ciated glutamate excitotoxicity. Indeed, microdialysis in the
striatum of xCT-deleted mice showed a 70% decrease of
extracellular glutamate (Massie et al., 2011). Excitotoxicity
remains one of the major mechanistic hypotheses in ALS
and riluzole, the only FDA-approved drug for ALS, has
anti-excitotoxic properties (Bensimon et al., 1994; Foran
and Trotti, 2009). Motor neurons are highly sensitive to
glutamate excitotoxicity (Takuma et al., 1999; Kawahara
et al., 2004; Van Den Bosch et al., 2006; Hideyama et al.,
2012), and astrocytic glutamate transporters are reduced in
rodent models and patients with ALS (Rothstein et al.,
1995; Howland et al., 2002). Additionally, elevated neur-
onal glutamate release was described in ALS mice
(Milanese et al., 2011). Now, with our microglia data a
new player is added to this excitotoxicity hypothesis for
ALS. Indeed, although microglia can release glutamate
through connexins (Takeuchi et al., 2006; Maezawa and
Jin, 2010), we show that system xC was the main source of
glutamate release by microglia, and that their activation led
to increased xCT expression and glutamate release.
Finally, we show a direct effect of system xC deletion on
the phenotype of microglia. Targeting of system xC mod-
ified release of glutamate but also changed the profile of
microglial-associated pro-inflammatory/neurotoxic (M1)
and anti-inflammatory/neuroprotective (M2) markers. Of
note, glutamate was shown to directly act on microglia
through their NMDA receptors, triggering their activation
and leading to secretion of pro-inflammatory/neurotoxic
(M1) factors (Kaindl et al., 2012). Our data show that
deletion of system xC resulted in less nitric oxide produc-
tion by activated microglial cells and decreased release of
pro-inflammatory cytokines TNFa and IL6 and the chemo-
kine MIP-1/CCL3. Likewise, expression analysis of micro-
glial associated M1/M2 markers in the spinal cord of xCT-
deleted mice showed levels of the anti-inflammatory/neuro-
protective (M2) marker Ym1/Chil3 to be strongly
increased, both in spinal cord and in isolated adult micro-
glial cells.
Importantly, we also measured the influence of xCT-de-
letion on the profile of microglial associated M1/M2 mar-
kers, during disease progression in spinal cords of ALS
mice. Indeed, M1/M2 profiles had previously been sug-
gested to reflect disease progression in hSOD1G93A ALS
mice, with a more pro-inflammatory (M1) profile rather
linked to fast disease progression and an anti-inflammatory
(M2) profile rather linked to slow disease progression
(Beers et al., 2011; Liao et al., 2012). Comparing our re-
sults from slow progressing hSOD1G37R ALS mice with the
data from fast progressing hSOD1G93A mice, we found that
for the M1 markers, NOX2 presented the same pattern of
increased expression until end stage; IL1b remained
increased until end stage in hSOD1G93A mice, whereas in
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slow progressing hSOD1G37R mice, levels slightly decreased
at the late symptomatic disease stage. Concerning the M2
marker Ym1/Chil3, although its increase during the early
symptomatic phase was similar in both models, decreased
expression at the late disease stage remained low until end
stage in hSOD1G93A mice, but surprisingly, increased again
in slow progressing hSOD1G37R mice. We believe that these
apparent discrepancies highlight that M1/M2 modulation
strongly depends on the inherent differences during the
symptomatic phase of fast and slow progressing ALS
mouse models.
With respect to the effect of xCT-deletion, two M2 mar-
kers, Ym1/Chil3 and Arg1, showed a striking effect. When
xCT-deleted ALS mice reached symptom onset earlier,
Ym1/Chil3 expression was decreased in the spinal cord
compared to xCT-containing ALS mice, whereas during
the late symptomatic stages, Ym1/Chil3 and Arg1 levels
were increased. These data suggested that a switch from
a M1 to a M2-like environment occurred and that this
could account for the observed slowing of ALS disease pro-
gression after onset of symptoms, in xCT-deleted ALS mice.
To date, it is not clear whether a switch from M1 to M2
could confer direct neuroprotection. In addition, classic M1
and M2 patterns are extremes of a spectrum of different
cell states (Xue et al., 2014) and in different injury and
disease models including ALS, microglia adopt a dual
phenotype, expressing factors that are hypothesized to be
both neurotoxic and neuroprotective (Chiu et al., 2013).
Futhermore, although M2 cells should be beneficial, periph-
eral injection of bone marrow cells differentiated to a M2-
phenotype worsened symptoms in hSOD1G93A mice
(Vaknin et al., 2011) (although actual CNS infiltration
was not detected). Additionally, decreasing the expression
of microglial M1 markers does not necessarily increase the
production of neurotrophic M2 factors, as seen after mino-
cycline injection (Kobayashi et al., 2013). However, delet-
ing NOX2 (known to increase ALS mouse survival) (Wu
et al., 2006; Marden et al., 2007) has been shown, both in
culture and acute CNS lesions, to decrease M1 marker ex-
pression (Choi et al., 2012).
Our finding of a beneficial effect of xCT deletion after
symptom onset in ALS mice is consistent with findings from
other models of neurodegenerative diseases. Suppression of
system xC in mouse or in in vitro models of Alzheimer’s
disease, Parkinson’s disease, multiple sclerosis and gliomas
demonstrated protection from neurodegeneration (Chung
et al., 2005; Qin et al., 2006; Domercq et al., 2007;
Massie et al., 2011). So far, contribution of system xC to
neurodegeneration was hinted at, but only using rather
acute models of neurodegenerative diseases. Our findings
with ALS mice now reveal disease contribution of system
xC in an actual progressive and chronic model of a neuro-
degenerative disease. These studies, combined with our
finding, strongly support the idea of a disease contribution
of system xC in neurodegenerative disorders in general.
In summary, while xCT/ microglial cells release less
M1-related factors (nitric oxide, TNFa, IL6, CCL3) and
xCT/ mice show increased expression of M2-related
Ym1/Chil3 in spinal cord and isolated microglial cells,
system xC seems to be a new regulator of microglial func-
tion. In addition, with its capacity to release glutamate and
the potential to contribute to excitotoxicity, we show evi-
dence that system xC could be implicated in motor neuron
degeneration in ALS mice. Thus, pharmacological blockage
of system xC, during the symptomatic phase (but not
before, to avoid negative early effects) could increase sur-
vival in ALS mice. However, for this, first better and more
specific system xC antagonists are needed (as commercially
available antagonists are not specific enough and their bio-
availability for the CNS not optimal). As ALS is a mainly
sporadic disease, targeting the symptomatic phase of the
disease would be relevant and could include focusing on
the M1/M2 microglial cell phenotype, possibly via
system xC.
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